» Articles » PMID: 11704864

Transcriptional Regulation of Bcl-2 by Nuclear Factor Kappa B and Its Significance in Prostate Cancer

Overview
Journal Oncogene
Date 2001 Nov 13
PMID 11704864
Citations 205
Authors
Affiliations
Soon will be listed here.
Abstract

This work presents direct evidence that the bcl-2 gene is transcriptionally regulated by nuclear factor-kappa B (NF-kappa B) and directly links the TNF-alpha/NF-kappa B signaling pathway with Bcl-2 expression and its pro-survival response in human prostate carcinoma cells. DNase I footprinting, gel retardation and supershift analysis identified a NF-kappa B site in the bcl-2 p2 promoter. In the context of a minimal promoter, this bcl-2 p2 site 1 increased transcription 10-fold in the presence of the p50/p65 expression vectors, comparable to the increment observed with the consensus NF-kappa B site, while for the full p2 promoter region transcriptional activity was increased sixfold by over-expression of NF-kappa B, an effect eliminated by mutating the bcl-2 p2 site 1. The expression of Bcl-2 has been linked to the hormone-resistant phenotype of advanced prostate cancer. Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line LNCaP observed in response to hormone withdrawal is further augmented by TNF-alpha treatment, and this effect is abated by inhibitors of NF-kappa B. Concomitantly, bcl-2 p2 promoter studies in LNCaP cells show a 40-fold increase in promoter activity after stimulation with TNF-alpha in the absence of hormone.

Citing Articles

iModEst: disentangling -omic impacts on gene expression variation across genes and tissues.

Sokolowski D, Mai M, Verma A, Morgenshtern G, Subasri V, Naveed H NAR Genom Bioinform. 2025; 7(1):lqaf011.

PMID: 40041206 PMC: 11879402. DOI: 10.1093/nargab/lqaf011.


BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.

Chong S, Lu J, Valentin R, Lehmberg T, Eu J, Wang J Mol Cancer. 2025; 24(1):62.

PMID: 40025512 PMC: 11874845. DOI: 10.1186/s12943-025-02260-7.


Increased CCL2/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC/BCL2 double-expressor DLBCL.

Kim S, Jeong H, Ahn H, Han B, Lee K, Song Y Blood Adv. 2024; 8(22):5773-5788.

PMID: 39293078 PMC: 11605354. DOI: 10.1182/bloodadvances.2024013699.


GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.

Zhou Y, Zhao H, Ren R, Zhou M, Zhang J, Wu Z Theranostics. 2024; 14(9):3470-3485.

PMID: 38948063 PMC: 11209725. DOI: 10.7150/thno.92646.


Pseudolaric Acid B Targets CD147 to Selectively Kill Acute Myeloid Leukemia Cells.

Zou S, Parfenova E, Vrdoljak N, Minden M, Spagnuolo P Int J Mol Sci. 2024; 25(12).

PMID: 38928225 PMC: 11203802. DOI: 10.3390/ijms25126517.